Breaking News Instant updates and real-time market news.

COLL

Collegium Pharmaceutical

$23.57

-0.45 (-1.87%)

, NKTR

Nektar

$27.95

0.55 (2.01%)

09:33
01/15/20
01/15
09:33
01/15/20
09:33

Nektar committee vote eliminates potential Collegium competitor, says Gabelli

Gabelli analyst Kevin Kedra said the unanimous FDA Advisory Committee vote of 27-0 against Nektar's (NKTR) oxycodegol reinforces his belief that the FDA will not be approving any new long-acting opioids in the near term and eliminates a potential opioid competitor to Collegium Pharmaceutical's (COLL) Xtampza. The current FDA AdCom is also reviewing Intellipharmaceutics' (IPCIF) Aximris XR, another new long-acting opioid formulation, and Kedra expects "a similar overwhelmingly negative vote this afternoon." Xtampza remains the most recently approved extended-release/long-acting opioid for pain on the U.S. market and he expects the status quo to remain for the intermediate future, said the analyst, who keeps a Buy rating on Collegium shares.

COLL

Collegium Pharmaceutical

$23.57

-0.45 (-1.87%)

NKTR

Nektar

$27.95

0.55 (2.01%)

IPCIF

Intellipharmaceutics

$0.00

(0.00%)

  • 13

    Feb

COLL Collegium Pharmaceutical
$23.57

-0.45 (-1.87%)

11/08/19
RHCO
11/08/19
NO CHANGE
Target $22
RHCO
Buy
Collegium Pharmaceutical price target raised to $22 from $16 at SunTrust
SunTrust analyst Gregg Gilbert raised his price target on Collegium Pharmaceutical to $22 and kept his Buy rating after its Q3 results, saying that with announced access wins, he is raising his modeled Xtampza ER market share for long-acting opioid to 5% from 4.3% in 2020. The analyst warns however that after spiking over 30% yesterday, the stock may "tread water" for a bit as investors consider the company's exposure to opioid litigation.
01/06/20
CANT
01/06/20
NO CHANGE
Target $24
CANT
Overweight
Collegium should continue growing in 2020 and beyond, says Cantor Fitzgerald
Cantor Fitzgerald analyst Brandon Folkes reiterates an Overweight rating on Collegium Pharmaceutical with a $24 price target. The analyst remains positive on the long-term growth potential of Xtampza, which he expects to be the leading branded extended-release oxycodone over time. Collegium will build itself into one of the leading pain-focused companies, Folkes tells investors in a research note. The company has made good progress with its exclusive contracting approach on Xtampza to-date, and the wins for 2020 "could be the significant catalyst needed to make it the leading branded long-acting oxycodone in the market," contends the analyst.
01/08/20
HCWC
01/08/20
NO CHANGE
Target $29
HCWC
Buy
Collegium Pharmaceutical price target raised to $29 from $25 at H.C. Wainwright
H.C. Wainwright analyst Oren Livnat raised his price target for Collegium Pharmaceutical to $29 from $25 saying the while the company's first-time 2020 revenue guidance is in-line with expectations, Xtampza ER upside is more important, and profitable, than Nucynta downside. The analyst keeps a Buy rating on the shares.
01/08/20
NEED
01/08/20
NO CHANGE
Target $36
NEED
Buy
Collegium Pharmaceutical price target raised to $36 from $28 at Needham
Needham analyst Serge Belanger raised his price target for Collegium Pharmaceutical to $36 from $28 and maintained a Buy rating after the company issued guidance for 2020 on Tuesday, saying Collegium expects Xtampza sales to grow to $150M-$160M in 2020 from $95M-$105M in 2019. He says there is potential for more significant Xtampza sales growth than implied by the 2020 guidance, but thinks Collegium erred on the conservative side given continued contraction across opioid markets. Based on Xtampza sales growth, the analyst expects Collegium to firmly cross the profitability threshold in 2020.
NKTR Nektar
$27.95

0.55 (2.01%)

01/10/20
HCWC
01/10/20
NO CHANGE
HCWC
Amended Nektar, Bristol pact reflects bempeg limitations, says H.C. Wainwright
No longer nine malignancies spread across 20 lines of treatment, the amended collaboration between Nektar Therapeutics (NKTR) and Bristol-Myers Squibb (BMY) limits bempeg to basically three tumor types, H.C. Wainwright analyst Debjit Chattopadhyay tells investors in a research note. While these programs are to be jointly funded, Bristol would independently conduct and fund a Phase 1/2 dose optimization and expansion study in first-line non-small-cell lung cancer with bempeg and nivolumab, which is a tacit admission of impeding competition from THOR-707, contends the analyst. He believes that should THOR-707 live up to its expectations, any wins for the bempeg combo "could prove to be ephemeral." Chattopadhyay keeps a Neutral rating on Nektar shares with a $32 price target.
01/10/20
MZHO
01/10/20
NO CHANGE
Target $21
MZHO
Neutral
Nektar briefing docs more negative than positive, says Mizuho
Mizuho analyst Difei Yang views the FDA's briefing documents today on NKTR-181 ahead of the anticipated January 14 panel meeting as "more negative than positive." The FDA notes that "NKTR-181 demonstrates an oral abuse potential comparable to oxycodone following oral administration," the analyst points out. Yang, however, does not expect NKTR-181 or the outcome of the panel meeting to have a meaningful impact on Nektar shares. The value of Nektar will continue to be driven by clinical development of NKTR-214, the analyst tells investors in a research note. She reiterates a Neutral rating on Nektar with a $21 price target. The stock is up 12% to $24.16 in morning trading.
01/10/20
PIPR
01/10/20
NO CHANGE
PIPR
Overweight
Nektar update with Bristol-Myers 'positive all around,' says Piper Sandler
Piper Sandler analyst Tyler Van Buren said news of the amended collaboration between Nektar Therapeutics (NKTR) and Bristol-Myers Squibb (BMY) was "a positive update all around" as he believes the new registrational trials in adjuvant melanoma and muscle-invasive bladder cancer essentially expand the commercial opportunity for what are two of the more promising datasets and Bristol's "reset" in first-line lung cancer "is a neutral announcement as no one provided credit for lung anyway" to Nektar. Van Buren, who also contends that "the refined development plan in RCC makes a ton of sense," keeps an Overweight rating on Nektar shares.
01/10/20
GSCO
01/10/20
NO CHANGE
GSCO
Goldman keeps Sell on Nektar despite amended Bristol-Myers Squibb agreement
Goldman Sachs analyst Paul Choi kept a Sell rating and $17 price target on Nektar Therapeutics (NKTR) following the company's amended collaboration agreement with Bristol-Myers Squibb (BMY), which he said provides visibility on the path forward for bempegaldesleukin + Opdivo. While the analyst expects Nektar to trade up following the news, he added that "in the absence of data we do not expect significant credit to be attributed to these additional indications in the near term."
IPCIF Intellipharmaceutics
$0.00

(0.00%)

TODAY'S FREE FLY STORIES

03:15
01/21/20
01/21
03:15
01/21/20
03:15
General news
FX Update: The biggest mover has been a decline in AUD-JPY »

FX Update: The biggest…

CCC

Clarivate Analytics

$18.90

1.24 (7.02%)

21:43
01/20/20
01/20
21:43
01/20/20
21:43
Upgrade
Clarivate Analytics rating change at Stifel »

Clarivate Analytics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

CCC

Clarivate Analytics

$18.90

1.24 (7.02%)

21:42
01/20/20
01/20
21:42
01/20/20
21:42
Hot Stocks
Clarivate Analytics acquires Decision Resources Group for $950M »

Clarivate Analytics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

BA

Boeing

$324.11

-7.89 (-2.38%)

20:05
01/20/20
01/20
20:05
01/20/20
20:05
Periodicals
Air Niugini delaying delivery of four 737 MAX jets, Reuters reports »

Papua New Guinea carrier…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

AVASF

Avast

$0.00

(0.00%)

20:01
01/20/20
01/20
20:01
01/20/20
20:01
Recommendations
Avast analyst commentary at Jefferies »

Avast set to deliver…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$339.56

0.89 (0.26%)

, CMCSK

Comcast

$0.00

(0.00%)

19:55
01/20/20
01/20
19:55
01/20/20
19:55
Hot Stocks
Fly Intel: Top five weekend stock stories »

Catch up on the…

NFLX

Netflix

$339.56

0.89 (0.26%)

CMCSK

Comcast

$0.00

(0.00%)

CMCSA

Comcast

$47.48

0.62 (1.32%)

TSLA

Tesla

$510.34

-3.065 (-0.60%)

BA

Boeing

$324.11

-7.89 (-2.38%)

GOOG

Alphabet

$1,480.28

28.34 (1.95%)

GOOGL

Alphabet Class A

$1,479.12

29.29 (2.02%)

SNE

Sony

$72.48

-0.07 (-0.10%)

KKR

KKR

$31.20

0.7 (2.30%)

TSM

TSMC

$58.58

-0.18 (-0.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 22

    Jan

  • 23

    Jan

  • 29

    Jan

  • 29

    Jan

  • 31

    Jan

  • 03

    Feb

  • 03

    Feb

  • 04

    Feb

  • 10

    Feb

  • 24

    Feb

  • 26

    Feb

  • 23

    Mar

  • 23

    Mar

HD

Home Depot

$231.90

3.07 (1.34%)

18:06
01/20/20
01/20
18:06
01/20/20
18:06
Periodicals
Mexican trade union suspends strike threat against Home Depot, Reuters says »

A top Mexican trade union…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

UCFC

United Community Financial

$11.56

-0.02 (-0.17%)

, FDEF

First Defiance Financial

$31.12

-0.1 (-0.32%)

18:00
01/20/20
01/20
18:00
01/20/20
18:00
Hot Stocks
First Defiance Financial receives approval for United Community Financial merger »

First Defiance Financial…

UCFC

United Community Financial

$11.56

-0.02 (-0.17%)

FDEF

First Defiance Financial

$31.12

-0.1 (-0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

FDEF

First Defiance Financial

$31.12

-0.1 (-0.32%)

17:56
01/20/20
01/20
17:56
01/20/20
17:56
Earnings
Breaking Earnings news story on First Defiance Financial »

First Defiance Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

T

AT&T

$38.36

0.33 (0.87%)

, CMCSA

Comcast

$47.48

0.62 (1.32%)

17:37
01/20/20
01/20
17:37
01/20/20
17:37
On The Fly
Box Office Battle: 'Bad Boys for Life' wins MLK Jr. weekend with $73M debut »

"Box Office Battle" is…

T

AT&T

$38.36

0.33 (0.87%)

CMCSA

Comcast

$47.48

0.62 (1.32%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$72.48

-0.07 (-0.10%)

LGF.A

Lionsgate

$10.96

-0.32 (-2.84%)

LGF.B

Lionsgate

$10.32

-0.305 (-2.87%)

DIS

Disney

$144.25

-0.85 (-0.59%)

VIACA

ViacomCBS

$43.26

-0.855 (-1.94%)

VIAC

ViacomCBS

$39.48

-0.57 (-1.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 29

    Jan

  • 04

    Feb

  • 04

    Feb

  • 06

    Feb

  • 06

    Feb

STIM

Neuronetics

$4.38

-0.01 (-0.23%)

17:00
01/20/20
01/20
17:00
01/20/20
17:00
Recommendations
Neuronetics analyst commentary at Piper Sandler »

Correction in Neuronetics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCMD

Tactile Systems

$60.76

-2.74 (-4.31%)

16:55
01/20/20
01/20
16:55
01/20/20
16:55
Recommendations
Tactile Systems analyst commentary at Piper Sandler »

Lawsuit may drag out into…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EFSC

Enterprise Financial

$48.49

0.16 (0.33%)

16:45
01/20/20
01/20
16:45
01/20/20
16:45
Earnings
Enterprise Financial reports Q4 EPS $1.09, consensus $1.09 »

Reports Q4 net interest…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

TGP

Teekay LNG

$14.73

-0.26 (-1.73%)

16:33
01/20/20
01/20
16:33
01/20/20
16:33
Hot Stocks
Teekay LNG Partners declares distribution of 19c per common unit »

Teekay GP, the general…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WES

Western Midstream

$20.60

-0.55 (-2.60%)

16:31
01/20/20
01/20
16:31
01/20/20
16:31
Hot Stocks
Western Midstream announces Q4 2019 distribution »

Western Midstream…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

CPG

Crescent Point Energy

$4.20

-0.08 (-1.87%)

16:29
01/20/20
01/20
16:29
01/20/20
16:29
Hot Stocks
Crescent Point closes sale of gas infrastructure assets »

Crescent Point announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHSCP

CHS Inc.

$28.85

0.13 (0.45%)

16:26
01/20/20
01/20
16:26
01/20/20
16:26
Hot Stocks
CHS Inc. names Olivia Nelligan as Chief Financial Officer »

CHS Inc. announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GMAB

Genmab

$22.73

-0.13 (-0.57%)

, JNJ

Johnson & Johnson

$149.07

0.82 (0.55%)

16:25
01/20/20
01/20
16:25
01/20/20
16:25
Hot Stocks
Genmab announces European Marketing Authorization for DARZALEX »

Genmab A/S (GMAB)…

GMAB

Genmab

$22.73

-0.13 (-0.57%)

JNJ

Johnson & Johnson

$149.07

0.82 (0.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 09

    Mar

  • 17

    Mar

PRPO

Precipio

$2.09

-0.02 (-0.95%)

16:25
01/20/20
01/20
16:25
01/20/20
16:25
Conference/Events
Precipio to host shareholder update conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jan

TILE

Interface

$17.37

0.23 (1.34%)

16:22
01/20/20
01/20
16:22
01/20/20
16:22
Hot Stocks
Interface names Dan Hendrix as President, CEO »

Interface announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBCP

Independent Bank

$22.51

-0.26 (-1.14%)

16:19
01/20/20
01/20
16:19
01/20/20
16:19
Hot Stocks
Independent Bank announces 11% increase in quarterly cash dividend »

Independent Bank…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 18

    Feb

  • 19

    Feb

JAZZ

Jazz Pharmaceuticals

$151.00

-0.56 (-0.37%)

16:17
01/20/20
01/20
16:17
01/20/20
16:17
Hot Stocks
Jazz Pharmaceuticals receives EU Marketing Authorization for Sunosi »

Jazz Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

AMRN

Amarin

$19.91

-0.15 (-0.75%)

16:13
01/20/20
01/20
16:13
01/20/20
16:13
Recommendations
Amarin analyst commentary at Jefferies »

Amarin remains in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$331.98

1.08 (0.33%)

, SPX

S&P 500

$0.00

(0.00%)

16:09
01/20/20
01/20
16:09
01/20/20
16:09
Periodicals
Macron, Trump declare truce in digital tax dispute, Reuters reports »

French President Emmanuel…

SPY

SPDR S&P 500 ETF Trust

$331.98

1.08 (0.33%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XOM

Exxon Mobil

$68.55

-0.26 (-0.38%)

, HES

Hess Corp.

$69.87

-0.45 (-0.64%)

16:07
01/20/20
01/20
16:07
01/20/20
16:07
Periodicals
Guyana's first oil cargo to be refined by Exxon in the U.S., Reuters reports »

A vessel carrying…

XOM

Exxon Mobil

$68.55

-0.26 (-0.38%)

HES

Hess Corp.

$69.87

-0.45 (-0.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

  • 31

    Jan

  • 23

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.